NASDAQ: ALIMAlimera Sciences Inc Stock
$3.63+0.04 (+1.11%)
Updated Apr 24, 2024
ALIM Price
$3.63
Fair Value Price
N/A
Market Cap
$190.05M
52 Week Low
$1.56
52 Week High
$4.38
P/E
-4.32x
P/B
4.12x
P/S
1.37x
PEG
N/A
Dividend Yield
N/A
Revenue
$80.75M
Earnings
-$20.13M
Gross Margin
86.6%
Operating Margin
-12.21%
Profit Margin
-26.5%
Debt to Equity
2.33
Operating Cash Flow
-$14M
Beta
0.88
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ALIM Overview
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ALIM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ALIM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ALIM is poor value based on its book value relative to its share price (4.12x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.06x)
P/B vs Industry Valuation
ALIM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ALIM due diligence checks available for Premium users.
Be the first to know about important ALIM news, forecast changes, insider trades & much more!
ALIM News
Valuation
ALIM fair value
Fair Value of ALIM stock based on Discounted Cash Flow (DCF)
Price
$3.63
Fair Value
$5.81
Undervalued by
37.53%
ALIM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ALIM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.32x
Industry
47.66x
Market
41.27x
ALIM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.12x
Industry
2.06x
ALIM is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ALIM's financial health
Profit margin
Revenue
$26.3M
Net Income
-$3.8M
Profit Margin
-14.4%
ALIM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ALIM's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$153.5M
Liabilities
$107.4M
Debt to equity
2.33
ALIM's short-term assets ($52.42M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALIM's long-term liabilities ($85.44M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALIM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ALIM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$3.8M
Investing
-$85.0k
Financing
-$78.0k
ALIM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ALIM vs Pharmaceutical Stocks
Alimera Sciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.